Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03793868 · ClinicalTrials.gov registry record · Early Phase 1

Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis

A Early Phase 1 study of Amyotrophic Lateral Sclerosis, sponsored by Mayo Clinic.

Completed
Registry status
Early Phase 1
Development phase
22
Enrollment target
1
Study location

NCT03793868 is a Early Phase 1 study of Amyotrophic Lateral Sclerosis that has completed, run by Mayo Clinic. The registered enrollment target is 22 participants, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03793868, a Early Phase 1 study of Amyotrophic Lateral Sclerosis, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Early Phase 1
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

To evaluate if transcranial magnetic stimulation can be used as a biomarker in Amyotrophic Lateral sclerosis (ALS).

Conditions Studied

Amyotrophic Lateral Sclerosis

Interventions

  • OTHER Placebo
  • DRUG Perampanel

Study Locations (1)

Florida

  • Mayo Clinic - Jacksonville

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2018-12-04
Est. Completion 2020-09-01
Phase Early Phase 1

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03793868

The ClinicalTrials.gov registry entry for NCT03793868 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (98% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03793868 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT03793868 about?

NCT03793868 is a clinical study titled "Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis". To evaluate if transcranial magnetic stimulation can be used as a biomarker in Amyotrophic Lateral sclerosis (ALS).

What is the current status of trial NCT03793868?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 22 participants. The study started on 2018-12-04. Estimated completion is 2020-09-01.

What conditions does trial NCT03793868 study?

This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.

What interventions are being tested in trial NCT03793868?

The interventions under investigation include: Placebo (OTHER), Perampanel (DRUG).

Who is sponsoring clinical trial NCT03793868?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03793868 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Amyotrophic Lateral Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Amyotrophic Lateral Sclerosis

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.